Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 32.96 USD 1.45%
Market Cap: 1.8B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SUPN stock under the Base Case scenario is hidden USD. Compared to the current market price of 32.96 USD, Supernus Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SUPN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.8
P/S
P/S
Price to Sales
2.8
vs History
47
vs Industry
41
Median 3Y
2.7
Median 5Y
2.7
Industry
2.4
Forward
2.9
More Details
24.9
P/E
P/E
Price to Earnings
24.9
vs History
50
vs Industry
19
Median 3Y
34.5
Median 5Y
27.3
Industry
20.8
Forward
16.5
More Details
10.7
P/OCF
P/OCF
Price to OCF
10.7
vs History
66
vs Industry
36
Median 3Y
14
Median 5Y
12.5
Industry
15.4
More Details
10.7
P/FCFE
P/FCFE
Price to FCFE
10.7
vs History
36
vs Industry
29
Median 3Y
9.5
Median 5Y
9.7
Industry
22.8
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
73
vs Industry
42
Median 3Y
1.9
Median 5Y
1.9
Industry
2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
88
vs Industry
49
Median 3Y
2.5
Median 5Y
2.6
Industry
2.5
Forward
2.2
More Details
2.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.3
vs History
88
vs Industry
66
Median 3Y
2.9
Median 5Y
2.9
Industry
4.9
More Details
8.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.1
vs History
71
vs Industry
37
Median 3Y
14.2
Median 5Y
11.3
Industry
12.7
Forward
6.3
More Details
15.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.3
vs History
52
vs Industry
28
Median 3Y
40.7
Median 5Y
17.3
Industry
15.8
Forward
10.7
More Details
8
EV/OCF
EV/OCF
Enterprise Value to OCF
8
vs History
80
vs Industry
43
Median 3Y
13.4
Median 5Y
12
Industry
14
More Details
8.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.1
vs History
82
vs Industry
34
Median 3Y
13.5
Median 5Y
12
Industry
18.3
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
17
vs Industry
43
Median 3Y
1.4
Median 5Y
1.4
Industry
1.7
More Details

Multiples Across Competitors

SUPN Competitors Multiples
Supernus Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
1.8B USD 2.8 24.9 8.1 15.3
US
Eli Lilly and Co
NYSE:LLY
704.7B USD 15.7 66.9 38.8 42.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
381.8B USD 4.3 27.1 12.7 16.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 18.9 12.5 14.2
CH
Roche Holding AG
SIX:ROG
210.4B CHF 3.6 18.2 10.3 12.2
UK
AstraZeneca PLC
LSE:AZN
168B GBP 4.1 31.3 126.4 193.1
CH
Novartis AG
SIX:NOVN
186.2B CHF 4.2 18.1 11 14.1
US
Merck & Co Inc
NYSE:MRK
212.5B USD 3.3 12.4 8.4 10
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
131.9B USD 2.1 16.5 8 11.5
P/E Multiple
Earnings Growth PEG
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average P/E: 26
24.9
35%
0.7
US
Eli Lilly and Co
NYSE:LLY
66.9
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.1
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.9
19%
1
CH
Roche Holding AG
SIX:ROG
18.2
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.3
36%
0.9
CH
Novartis AG
SIX:NOVN
18.1
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.4
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBITDA: 394.7
8.1
-15%
N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
15%
0.8
CH
Roche Holding AG
SIX:ROG
10.3
8%
1.3
UK
AstraZeneca PLC
LSE:AZN
126.4
9%
14
CH
Novartis AG
SIX:NOVN
11
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.4
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8
3%
2.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBIT: 1 698.5
15.3
33%
0.5
US
Eli Lilly and Co
NYSE:LLY
42.8
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.7
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
16%
0.9
CH
Roche Holding AG
SIX:ROG
12.2
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
193.1
21%
9.2
CH
Novartis AG
SIX:NOVN
14.1
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.5
10%
1.1

See Also

Summary
SUPN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUPN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUPN stock valuation using valuation multiples.
Wall Street Estimates
SUPN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUPN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.